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Abstract. A patent foramen ovale (PFO) is found with
increased frequency in patients with stroke of unde-
termined origin but the significance and therapeutic
implications of this observation remain unclear. Sev-
eral lines of evidence suggest a role for the PFO in
stroke pathophysiology for some cryptogenic stroke pa-
tients, such as those whose PFO is accompanied by a
prothrombotic state, atrial septal aneurysm, or lower
extremity/pelvic DVT. Diagnostic evaluation of the pa-
tient with cryptogenic stroke and PFO is directed at
identifying these subgroups. Appropriate therapy for
primary and secondary stroke prevention in a subject
with a PFO remains unclear given current uncertain-
ties as to the pathophysiological significance of PFO.
Additional studies are needed, such as those focused on
lower extremity veins or the cardiac interatrial septum,
to guide therapy in specific stroke subpopulations.
Key Words. cryptogenic stroke, stroke, patent foramen
ovale, deep venous thrombosis, treatment
Stroke is the leading cause of adult disability. Stroke
is also the third leading source of mortality in the
U.S., accounting for approximately 1 in 15 deaths [1].
There are over 730,000 new strokes diagnosed each
year in the U.S. [2].
The young account for a significant fraction of
these strokes. Though the median age of stroke in
the U.S. is 72 years, approximately 28% of strokes oc-
cur in patients who are under age 65 [1]. In one U.S.
study, 8% of all strokes occurred in patients between
the ages of 20 and 45 [3]. In a large Japanese study,
7% of strokes occurred in patients age 16–50 [4]. This
rate may be lower in European, and higher in devel-
oping, countries [5]. The one-month case fatality rate
after ischemic stroke in patients <45 years of age
is approximately half that of patients >45 [3]. Thus
young stroke patients survive a long time, emphasiz-
ing the importance of secondary stroke prevention in
this population.
There are many causes of stroke in general and
this is equally true in younger stroke patients, where
pathogenesis is often different from stroke in older
patients [6]. Often no cause for stroke is apparent, in
which case the stroke is termed cryptogenic.
The fraction of strokes that remains cryptogenic
after careful evaluation is substantial and is in-
creased in younger stroke patients. Across all pa-
tients with ischemic stroke, 30–40% are cryptogenic
[7–12]. Studies suggest that this fraction is increased
in younger patients. For example, one study found
that the fraction of ischemic strokes that are cryp-
togenic in patients age 20–45 is 31% higher than in
patients over 45 years [3]. In a study of patients <55
years of age, no cause for stroke was apparent in 64%
of patients [13].
Cryptogenic stroke likely represents a number
of different disease processes. Nevertheless, a large
fraction of patients with a cryptogenic stroke share
certain clinical features. Chief among these is an in-
creased prevalence of a patent foramen ovale (PFO)
[14].
Anatomic closure of the foramen ovale normally
follows functional closure after birth, but a patent
interatrial communication remains in a fraction of
healthy subjects. One study found [15] that 6% of
subjects had a PFO that was pencil patent (>5 mm
diameter) and 29% of subjects had a PFO that was
probe patent (2–5 mm). More recently, Hagen et al.
[16] found that across all subjects at autopsy, 27.3%
of subjects had a PFO, with mean diameter of 5
mm. Interestingly, this study also found that sub-
jects <age 30 years had a higher prevalence of PFO,
34.3%, suggesting that the impact of any disease
processes directly related to a PFO may be greater
in younger patients. Echocardiographic studies have
varied in their estimates of PFO prevalence among
healthy subjects, but results are generally lower than
values found in autopsy studies. This suggests that
echocardiography has reduced sensitivity for iden-
tifying PFO as compared to anatomical inspection.
The prevalence of PFO found in most echocardiog-
raphy studies of healthy subjects has been between
10% [17] and 22% [18].
A PFO has been found to be present more of-
ten in patients with cryptogenic stroke than in pa-
tients with stroke of determined origin [13,17–27] or
in healthy controls [13,17,18,21,28–30]. A PFO with
concomitant atrial septal aneurysm is also found
more often in patients with cryptogenic stroke, par-
ticularly younger patients [14]. The dual diagnosis of
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PFO and atrial septal aneurysm may have a particu-
larly important association with stroke recurrence as
vs. either diagnosis alone [31,32]. However, some au-
thors have suggested that an atrial septal aneurysm
may in part be a reflection of a larger PFO size [33].
Determination of PFO prevalence is made dif-
ficult by variability in the diagnostic sensitivity
of current noninvasive methods. The sensitivity of
transesophageal echocardiography (TEE) may be as
much as two-fold greater than that of transtho-
racic echocardiography (TTE) for diagnosing a PFO
[18,34], though addition of harmonic imaging us-
ing saline contrast can the sensitivity of TTE [35].
Transcranial Doppler (TCD) has sensitivity that ap-
proaches that of TEE [22,36,37], but decreased speci-
ficity. While TCD provides less information on car-
diac structure as vs. echocardiography, it may be
more sensitive to extracardiac right-to-left shunts.
The choice of vein used to introduce echo contrast in-
fluences diagnostic sensitivity, as blood entering the
right atrium via the inferior vena cava is more di-
rected towards the interatrial septum region where
a PFO is found, as compared to blood entering the
right atrium via the superior vena cava. Thus, stud-
ies have found a 2.5-fold increase in diagnostic sen-
sitivity for a PFO when agitated saline contrast was
injected via the femoral vein rather than the antecu-
bital vein [38,39].
The consistent observation that cryptogenic
stroke is associated with an increased prevalence of
PFO suggests the hypothesis that, in some of these
patients, the PFO is a source or a conduit for thrombi
that embolize to the brain. Other clinical character-
istics commonly found in patients with cryptogenic
stroke provide support for this hypothesis. First, the
topography of cerebral infarct in patients with cryp-
togenic stroke and PFO is often suggestive of an
embolic mechanism [7,26]. Second, several studies
suggest that PFO size is greater in patients with
cryptogenic stroke as compared to normal subjects or
patients with stroke of determined origin [23,24,26–
28,40,41]. However, PFO size is not related to risk
of stroke recurrence [27,42]. Third, the prevalence
of PFO patency at rest, i.e., without induction of a
Valsalva-related pressure gradient, may be greater
in patients with stroke as compared to control sub-
jects [30].
A fourth line of evidence that in some patients may
link PFO with pathophysiology of cryptogenic stroke
is a significant prevalence of lower extremity deep
venous thrombosis (DVT) in this patient population.
Gautier et al. [43] performed venography 2 days to
7 months after cryptogenic TIA or stroke and found
that 3/23 patients with PFO had leg DVT and 3 oth-
ers had left common iliac vein compression. Ranoux
et al. [25] performed venography within 4 weeks of
cryptogenic stroke and found that 1/13 patients with
PFO had a leg DVT. Lethen et al. [34] performed
venography an average of 8 days after TIA or stroke
of suspected cardiac origin and found that 5/53 pa-
tients with PFO had iliac or calf DVT. Stollberger et
al. [44] found a leg or pelvic DVT in 19/29 patients
with PFO and a cryptogenic arterial embolus, most
of which affected the cerebral circulation. The preva-
lence of DVT was higher among patients studied
within 1 week of embolus as compared to those stud-
ied 8–90 days post-event. Cramer et al. [45] found
that 9/46 patients with cryptogenic stroke and PFO
studied with MRI venography (MRV) an average of
2 days after stroke had evidence for a pelvic DVT.
There are a number of limitations in interpret-
ing data linking DVT with PFO-related stroke. Most
studies addressing this point have evaluated only a
subset, rather than a consecutive cohort, of stroke
patients. An additional limitation is that many stud-
ies have evaluated only part of the lower extremity
venous system, or have used methods with limited
sensitivity in portions of the lower extremity venous
system. Another frequent limitation has been the
absence of an appropriate control group, an impor-
tant concern given the substantial increase in DVT
prevalence that is found beginning with the fourth
day post-stroke [46,47]. These observations might
explain why reported rates of DVT have varied so
widely in prior studies of patients with PFO and cryp-
togenic stroke.
Data on prothrombotic states bolster the link be-
tween DVT and cryptogenic stroke. Bendixen et al.,
in a study of 1,943 patients, concluded that pro-
thrombotic states are a particularly important con-
sideration in patients 15–35 years of age [6] Pezzini
et al. [48] found that PFO played a pathogenic role
in 36 of 125 young (mean age 35 years) patients
with ischemic stroke. Among these 36, the prevalence
of a prothrombotic genetic variant, particularly the
prothrombin G20210A variant, was significantly in-
creased as compared to patients in whom PFO was
either absent or unrelated to stroke.
One issue that may be of particular importance
in this regard is evaluation of calf veins. Isolated calf
vein DVT is more common than DVT in any other site
following stroke [46,49] and at autopsy [50] and so
may be important before stroke, too. Proximal prop-
agation may occur in 20–28% of calf vein DVT [51,52].
Embolization can occur without propagation, for ex-
ample, an isolated calf DVT was found at autopsy
in 36–46% of patients with PE [53]. Emboli from
calf vein thrombi tend to be small and asymptomatic
on reaching the lung [54,55], and in general medi-
cal practice, little emphasis is placed on treatment of
calf vein DVT when extension to popliteal veins does
not occur [56]. However, an embolus from a calf vein
might be of substantially greater clinical significance
upon reaching the cerebral circulation [57], and the
incidence of paradoxical embolism in patients with
acute pulmonary embolism has been estimated to be
as high as 60% [58]. DVT from calf veins may not
be rare and, while of little significance to the lungs,
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can cause serious brain injury upon reaching the ar-
terial circulation. A recent case series described sev-
eral cryptogenic stroke patients with a calf vein DVT
and PFO in whom the calf DVT was established as
the cause of stroke on a probable basis [59].
Study of the pelvic veins may also be important in
the context of PFO-related stroke. In autopsy studies
of patients with a paradoxical embolism, the pelvic
veins were the only source of thromboemboli in 22%
of patients [60,61]. A consecutive study of 769 MRI
venograms [62] found that 20% of the 167 DVT iden-
tified were isolated to the pelvic veins. Pelvic DVT
have been described in patients with cryptogenic pul-
monary embolism [63–65] and in patients with cryp-
togenic stroke with PFO [59,66–68].
The Paradoxical Embolism from Large Veins in
Ischemic Stroke (PELVIS) study [45] performed a
pelvic MRV within 72 hours of stroke onset in young
(18–60 year-old) consecutive stroke patients at five
U.S. academic centers. Testing to identify the cause
of stroke was subsequently performed during hospi-
talization. This study was designed to test the hy-
pothesis that patients with cryptogenic stroke have
an increased prevalence of pelvic DVT as compared to
patients with stroke of determined origin. This time
cutoff of 72 hours was selected to minimize the influ-
ence of DVT arising after stroke onset. The age cut-
off was selected to focus on young stroke patients, in
whom the link between PFO and cryptogenic stroke
is strongest [14]. Enrolled patients were mean age
46 years. The PELVIS study found that, compared
to those with stroke of determined origin (n = 49),
patients with cryptogenic stroke (n = 46) were sig-
nificantly younger, had a higher prevalence of PFO
(61% versus 19%), and had less atherosclerosis risk
factors. Most importantly, cryptogenic patients had
more MRV scans with a high probability for pelvic
DVT (20%) than patients with stroke of determined
origin (4%, P < 0.03), with most of these having an
appearance of a chronic DVT. The most commonly
involved vein was the external iliac vein, followed
by common iliac vein, consistent with a prior report
of pelvic DVT distribution [62]. A limitation of this
study was that inter-rater reliability for MRV inter-
pretation was not high.
Further studies are needed to understand the
significance of calf, pelvic, and other DVT in the
pathogenesis of PFO-associated cryptogenic stroke.
Lower extremity venous duplex does not include
study of calf veins in some institutions, but iden-
tification of such small DVT might be necessary
in the context of cryptogenic stroke. Imaging the
pelvic veins has traditionally been limited. Bilateral
contrast venography and other diagnostic methods
have reduced diagnostic sensitivity for pelvic DVT
[47,69,70]. MRI venography was of diagnostic value
in the PELVIS study [45], but inter-rater reliabil-
ity was not high. A number of investigators are
currently examining improved methods to image
lower extremity/pelvic veins, including gadolinium-
enhanced MR venography [71], MR direct thrombus
imaging [72], venous enhanced subtracted peak
arterial MRV [73], CT venography [63,64], and
signal-enhanced Doppler [74].
Even as the pathophysiology of cryptogenic stroke
continues to be studied, clinicians have recognized
that medical therapy in patients with a cryptogenic
stroke may be associated with an important stroke
recurrence rate, the precise extent of which remains
unclear. In patients with cryptogenic stroke/TIA, re-
ported annual rates of recurrence have included 16%
[75], 5.4% [30], 3.4% [76], and 3.8% (84% were cryp-
togenic in this study) [77], Mas et al. [31] found a
stroke recurrence rate of 1% when both PFO and
atrial septal aneurysm were absent vs. 3.8% when
both were present. A recent large, prospective study
found that the combined annual rate of death or re-
current ischemic stroke among patients with crypto-
genic stroke was 7.8% [9], though a substudy found
that the annual rate of death/recurrent stroke after
a cryptogenic stroke was not significantly different
when PFO was (7.2%) or was not (6.4%) present [27].
A recent meta-analysis concluded that “PFO is not
associated with increased risk of subsequent stroke
or death among medically treated patients with cryp-
togenic stroke. However, both PFO and ASA possi-
bly increase the risk of subsequent stroke (but not
death) in medically treated patients younger than
55 years.” [32]. Future studies might examine the
hypothesis that specific subgroups of patients with
PFO and stroke can be identified in whom the risk of
stroke recurrence is increased [78].
There are several therapeutic options available for
primary and secondary stroke prevention in a person
with a confirmed PFO, including antiplatelet agents,
anticoagulation, and closure of the PFO via either
a transcatheter or surgical approach. The risk-to-
benefit ratio among these choices, however, remains
unclear [79].
Complicating therapeutic decision-making in this
context is the fact that, in most patients, no clear
understanding of the role of a PFO in stroke patho-
genesis is present. A PFO is not in itself a patho-
logical finding—the 27–29% [15,16] prevalence of
this cardiological variant in healthy people indicates
current existence of nearly two billion PFOs world-
wide. Treatment of PFO will be best directed when
a physician is able to understand the pathophysio-
logical events being targeted, and these events re-
quire further study. While considerable evidence cor-
relates presence of PFO with occurrence of crypto-
genic stroke, especially in younger patients, this link
could reflect several different possibilities across the
broad patient population. For example, the link could
reflect a second, co-linked pathophysiology that re-
sults in stroke such as atrial arrhythmias [80] or
other cardiac electrophysiological changes [81], it
could indicate PFO as the site of cardiac embolism
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formation, or it could reflect PFO as a conduit for
passage of paradoxical embolism. It is not surprising
that for some stroke subpopulations, recurrence of
ischemic brain events has been found not to be rare
despite complete PFO closure [82].
In the absence of a clear pathophysiological un-
derstanding, therefore, treatment of PFO-related
stroke remains controversial. Some experts recom-
mend that secondary stroke prevention in a patient
with a cryptogenic stroke, with or without PFO, is
generally achieved with an antiplatelet agent [83].
Retrospective data suggest that coumadin is superior
to antiplatelet therapy [84]. Consistent with this, one
model suggests that if the estimated risk of paradox-
ical stroke recurrence is >0.8% per year, secondary
stroke prevention should be achieved with either an-
ticoagulation or PFO closure [85]. Our practice has
been that, until prospectively collected data support
widespread use of anticoagulation in patients with
PFO and ischemic stroke, coumadin is indicated only
in patients with an appropriate therapeutic target.
Examples include a prothrombotic state or ischemic
stroke arising from a DVT passing through a PFO
as a paradoxical embolism on a probable basis. We
have defined ‘probable basis’ [59] as diagnosis of a
DVT less than 4 days [46] after stroke onset in the
presence of either PFO or atrial septal defect.
The role of PFO closure for primary or secondary
stroke prevention also remains unclear. There are
currently limited data directly comparing closure
with best medical therapy in patients with stroke,
and this question is currently being evaluated in
prospective controlled trials [86]. PFO closure may
be especially efficacious in specific patient subpopu-
lations. Corollary investigations might therefore at-
tempt to define such subpopulations, for example,
on the basis of prothrombotic state, migraine sta-
tus, measures of brain white matter injury, features
of cardiac interatrial anatomy, or electrophysiologi-
cal cardiac assessments. Recommendations [87] that
certain features of history should prompt PFO clo-
sure would be of increased value if studied in prospec-
tive controlled trials.
Diagnostic evaluation of a patient with crypto-
genic stroke and PFO currently attempts to identify
abnormalities that would best direct therapy. Identi-
fication of a DVT, especially less than four days [46]
after stroke onset, suggests paradoxical thromboem-
bolism and a need for anticoagulation. We therefore
try to study calf, popliteal, femoral, and pelvic veins
when possible. Identification of a prothrombotic state
might also suggest anticoagulation, and so hemato-
logical evaluation for both venous and artieral hyper-
coagulabile states is performed. Some authors recom-
mend transesophageal echocardiogram for measure-
ment of PFO and/or interatrial septum size to guide
the decision for PFO closure [87].
PFO is common in healthy human subjects. The
frequency of PFO is increased among patients with
a cryptogenic stroke. Several lines of evidence sug-
gest a role for the PFO in stroke pathophysiology for
some patients, particularly those with a concomitant
prothrombotic state, atrial septal aneurysm, or lower
extremity/pelvic DVT. New treatments to safely close
PFO are under evaluation [86,87]. A method to iden-
tify patients most likely to achieve long-term benefit
from this intervention remains to be established. In
this regard, a paradigmatic shift in thinking about
small lower extremity DVT may be needed to under-
stand stroke pathogenesis in patients with crypto-
genic stroke, as emboli of no significance to the lung
could, upon reaching the arterial circulation, cause
substantial brain ischemia and disability. Prevent-
ing TIA, stroke, and death after a diagnosis of cryp-
togenic stroke may be best guided by a better a more
precise understanding of the various pathophysiolo-
gies underlying PFO-associated cryptogenic stroke.
In the absence of such data, divergent therapeutic
strategies have been recommended [83,85,87].
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